Accounting Manager (Contractor)

Job Description: Accounting Manager (Contractor – 6 Months to cover an LOA)

Reporting to the Assistant Controller, this individual will serve as an integral team member with exposure to multiple facets of business operations.  The Accounting Manager will be responsible for leading or supporting many of Elicio’s accounting activities, including general ledger, monthly/quarterly close process, payroll, treasury, internal controls, and financial reporting. The Accounting Manager will work closely with the various members of the Company.  

Elicio Therapeutics (ELTX) is a growing organization based out of the Seaport area of Boston, Massachusetts with additional staff functioning in a virtual based environment from the Greater Boston area and throughout the United States. 

Major Duties/Responsibilities

• Lead day-to-day close and accrual processes including preparing/reviewing journal entries.
• Own preparation of monthly R&D accruals including collaborating with department leaders and outside contract research organizations.
• Prepare quarterly stock compensation calculations.
• Prepare warrant liability calculations.
• Manage leases including maintaining the reconciliations and booking the monthly journal entries.
• Prepare internal reporting package.
• Oversee senior accountant including supervision of tasks and review of reconciliations/journal entries
• Ownership of AP & payroll
• Promote a culture of collaboration, cooperation, cross functional inclusion, execution excellence, effective communication and cross-functional problem-solving to become a high-performing team.
• Other AD HOC projects.

Education & Professional Experience

Required:

• Degree in Business, Accounting or Finance, Master's degree preferred.
• 5+ years of relevant accounting experience in biotech or life sciences industry. Prior public accounting experience preferred

Skills:

• NetSuite experience preferred
• Strong working knowledge in general ledger, GAAP, AP, payroll, and accruals
• Proficiency in Microsoft Office applications required, including Excel and Word
• Excellent communication skills, with the ability to collaborate effectively with cross-functional teams
• Strong team player with the ability to work in a fast-paced environment, manage competing priorities, while filling gaps as needed

Working Conditions: Busy office/laboratory environment with frequent deadlines and interruptions

Travel: Travel is not required

Physical Requirements: Subject to periods of sitting or standing, vision is required to monitor data.

About Elicio Therapeutics

Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology company advancing a pipeline of novel lymph node-targeted immunotherapies for the treatment of some of the most aggressive cancers. By combining expertise in immunology and immunotherapy, Elicio is harnessing the natural power of the immune system with the AMP technology, which allows for therapeutic payloads to be delivered directly to the lymph nodes, with the goal of enhancing the immune system’s cancer-fighting capabilities. By targeting cancer immunotherapies to the core of the immune response, AMP aims to optimize the lymph nodes’ natural ability to educate, activate and amplify cancer-specific T cells, which are essential for recognizing and eliminating tumor cells. Engineered to synchronize immunity in these highly potent sites, AMP is built to enhance the magnitude, potency, quality and durability of the immune response to drive antitumor activity. The Company’s R&D pipeline includes off-the-shelf therapeutic cancer vaccines ELI-002, (targeting mKRAS-driven cancers) as well as ELI-007 and ELI-008 (targeting BRAF-driven cancers and p53 hotspot mutations, respectively). For more information, please visit www.elicio.com.

About the Amphiphile Platform 

Elicio Therapeutics’ proprietary Amphiphile (“AMP”) platform delivers investigational immunotherapeutics directly to the “brain center” of the immune system – the lymph nodes. Elicio believes this site-specific delivery of disease-specific antigens, adjuvants and other immunomodulators may efficiently educate, activate, and amplify critical immune cells, potentially resulting in induction and persistence of potent adaptive immunity required to treat many diseases. In preclinical models, Elicio has observed lymph node-specific engagement driving therapeutic immune responses of increased magnitude, function and durability. Elicio believes our AMP lymph node-targeted approach will produce superior clinical benefits compared to immunotherapies that do not engage the lymph nodes based upon preclinical studies. Elicio’s AMP platform, originally developed at the Massachusetts Institute of Technology has broad potential in the cancer space to advance a number of development initiatives through internal activities, in-licensing arrangements or development collaborations and partnerships. The AMP platform has been shown to deliver immunotherapeutics directly to the lymph nodes by latching on to the protein albumin, found in the bloodstream, as it travels to lymphatic tissue. In preclinical models, Elicio has observed lymph node-specific engagement driving immune responses of increased magnitude, function and durability.

***NO EXTERNAL AGENCIES